Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
PR Newswire•14/10/2026•07:05 ET
7
Key Highlights
- ➤Oral VK2735 enters Phase 3 SUNRISE program for obesity and type 2 diabetes
- ➤SUNRISE-1 and SUNRISE-2 each target 560 adults over 68 weeks
- ➤Trials test daily doses of 27.5 mg, 35 mg, 55 mg, or placebo
- ➤Phase 2 oral VK2735 delivered up to 12.2% weight loss at 13 weeks
- ➤Subcutaneous VK2735 Phase 3 VANQUISH trials fully enrolled approximately 5,500 adults
Expert Statements
Brian Lian, Chief Executive Officer of Viking Therapeutics
“Advancing the oral tablet formulation of VK2735 into Phase 3 is an exciting step toward expanding Viking's portfolio of therapeutic treatments for obesity”
Brian Lian, Chief Executive Officer of Viking Therapeutics
“Oral VK2735 represents the most advanced oral dual GLP-1/GIP agonist in clinical development and has the potential to be positioned as either an induction therapy or in the maintenance setting, increasing the treatment options available to patients and clinicians.”
Brian Lian, Chief Executive Officer of Viking Therapeutics
“Obesity is a chronic disease that often requires long-term treatment, making convenience and ease of use important considerations for supporting patients throughout their treatment journey.”
Brian Lian, Chief Executive Officer of Viking Therapeutics
“We believe a once-daily oral therapy could offer a flexible dosing option that may support improved treatment adherence over time.”
Brian Lian, Chief Executive Officer of Viking Therapeutics
“Oral VK2735, together with our subcutaneous formulation, which is currently in the Phase 3 VANQUISH registration program, could provide clinicians and patients with greater choice in selecting an approach to weight loss and long-term management that best meets the needs of individual patients.”
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity PR Newswire
SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes
Get started
Create a free account to read the full story.